+91 44 2496 8000 info@caplinpoint.net

CAPLIN STERILES GETS USFDA APPROVAL FOR LEVETIRACETAM IN SODIUM CHLORIDE INJECTION, INFUSION BAGS

Chennai, Jan 17, 2025: Caplin Steriles Limited (Caplin), a Subsidiary Company of Caplin Point Laboratories Limited (BSE: CAPPL (524742), NSE: CAPLIPOINT), has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Levetiracetam in Sodium Chloride Injection, 500mg/100mL, 1000mg/100mL and 1500mg/100mL infusion bags (Large Volume…

Read More »

CAPLIN POINT RECEIVES ESTABLISHMENT INSPECTION REPORT (EIR) FROM FDA WITH ZERO 483 OBSERVATIONS

Chennai, January 06, 2025: Caplin Point Laboratories Ltd. (“Caplin Point” or the “Company”) (BSE: 524742 | NSE: CAPLIPOINT), announced today that it has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for the recent inspection conducted at Caplin Steriles’ injectable and ophthalmic manufacturing facility located at Gummidipoondi. The unannounced…

Read More »